Rep. Gilbert Ray Cisneros, Jr. Acquires Shares of Insulet Corporation (NASDAQ:PODD)

Key Points

• Rep. Gilbert Ray Cisneros Jr. purchased $1,001–$15,000 of Insulet shares on August 18, disclosed in a September 10 filing through a Bank of America trust account.
• Insulet reported a strong latest quarter, with EPS of $1.66 versus $1.47 expected and revenue of $801.7 million, up 23.5% year over year. The stock opened at $131.96, well below its 12-month high of $354.88.
• Analyst sentiment is mixed: Insulet has an overall “Hold” consensus and a $195.40 average price target, following several target cuts and BTIG’s downgrade to “neutral.”

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Insulet Corporation (NASDAQ:PODD). In a filing disclosed on September 10th, the Representative disclosed that they had bought between $1,001 and $15,000 in Insulet stock on August 18th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of DoorDash NASDAQ: DASH on 8/28/2026.
• Purchased $15,001 - $50,000 in shares of Quanta Services NYSE: PWR on 8/27/2026.
• Purchased $15,001 - $50,000 in shares of Eaton NYSE: ETN on 8/27/2026.
• Sold $15,001 - $50,000 in shares of NIKE NYSE: NKE on 8/27/2026.
• Sold $1,001 - $15,000 in shares of Phreesia NYSE: PHR on 8/26/2026.
• Purchased $1,001 - $15,000 in shares of Wheaton Precious Metals NYSE: WPM on 8/26/2026.
• Purchased $1,001 - $15,000 in shares of Walmart NASDAQ: WMT on 8/26/2026.
• Purchased $1,001 - $15,000 in shares of The Goldman Sachs Group NYSE: GS on 8/26/2026.
• Sold $15,001 - $50,000 in shares of Lamar Advertising NASDAQ: LAMR on 8/25/2026.
• Sold $1,001 - $15,000 in shares of Phreesia NYSE: PHR on 8/25/2026.

Insulet Stock Performance

Shares of PODD stock opened at $131.96 on Friday. Insulet Corporation has a 12-month low of $126.40 and a 12-month high of $354.88. The business's fifty day simple moving average is $152.36 and its 200-day simple moving average is $173.92. The company has a current ratio of 2.48, a quick ratio of 1.83 and a debt-to-equity ratio of 0.65. The company has a market cap of $9.15 billion, a PE ratio of 24.67, a PEG ratio of 1.06 and a beta of 1.08.

Insulet (NASDAQ:PODD - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share for the quarter, topping analysts' consensus estimates of $1.47 by $0.19. Insulet had a return on equity of 29.29% and a net margin of 12.29%.The firm had revenue of $801.70 million during the quarter, compared to analysts' expectations of $787.39 million. During the same quarter last year, the firm earned $1.17 EPS. The business's quarterly revenue was up 23.5% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.460- EPS. Analysts expect that Insulet Corporation will post 6.51 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Bank of America cut their price objective on shares of Insulet from $288.00 to $208.00 and set a "buy" rating on the stock in a report on Monday, May 18th. JPMorgan Chase & Co. reissued a "neutral" rating and issued a $152.00 target price (down from $275.00) on shares of Insulet in a research report on Thursday, August 6th. Evercore set a $180.00 price target on Insulet in a research note on Monday, July 6th. Raymond James Financial reaffirmed an "outperform" rating and set a $180.00 target price on shares of Insulet in a report on Thursday, August 6th. Finally, BTIG Research cut shares of Insulet from a "buy" rating to a "neutral" rating in a research note on Thursday, August 6th. Fourteen analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Insulet currently has an average rating of "Hold" and a consensus price target of $195.40.

Institutional Investors Weigh In On Insulet

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Larson Financial Group LLC lifted its stake in shares of Insulet by 114.6% in the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier's stock valued at $25,000 after purchasing an additional 47 shares during the last quarter. University of Texas Texas AM Investment Management Co. acquired a new position in Insulet in the fourth quarter valued at about $26,000. Elyxium Wealth LLC purchased a new position in Insulet during the fourth quarter worth about $28,000. DV Equities LLC purchased a new position in Insulet during the fourth quarter worth about $28,000. Finally, MV Capital Management Inc. acquired a new stake in shares of Insulet during the fourth quarter valued at about $29,000.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Insulet Company Profile

Insulet Corporation is a medical device company that develops, manufactures and sells wearable insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company's principal product platform is Omnipod, a tubeless, wearable insulin pump system. Omnipod products include the disposable, wearable Pod and related management and smartphone-based technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.